Table 2.

Clinico-pathological features of the 4 molecular prognostic groups of endometrial carcinoma.

Molecular Prognostic Group	Age	BMI	Stage >I	High Grade	Non- Endometrioid Histotype	LVSI	Deep Myometrial Invasion	Lymph Node Involvement
POLE-mutated	58.5 ± 2.7	27.2 ± 0.9	6.3%	39.6%	13.9%	32.7%	27.3%	0%
MMR-deficient	66.5 ± 0.6	30.6 ± 1.2	27.4%	47.4%	14.2%	41.3%	44.5%	9.9%
p53-abnormal	71.1 ± 0.5	29.1 ± 0.5	49.2%	90%	73%	13.8%	48.9%	23.7%
NSMP	64.2 ± 1.9	32.3 ± 1.4	19.5%	15.6%	3.3%	48.8%	27.4%	4.3%